Journal of Molecular Biomarkers and Clinical Trials

Biomarkers for the Neglected Chagas Disease: How Remarkable!

Published on: 2016-05-09

Abstract

Chagas disease or American trypanosomiasis, caused by the etiological agent Trypanosoma cruzi, affects at least 8 million people in Central and South America. Morbidity is relatively high. The acute phase is followed by an asymptomatic phase, but roughly 30% of infected patients change to a symptomatic, chronic phase characterized by either severe cardiac or digestive forms.

Keywords

Parasitological, Trypanosoma cruzi, Inflammation and cellular injury biomarkers, Metabolic biomarkers, Prothrombotic biomarkers, Antigenic biomarkers